refero 550 mg filmom obalené tablety
alfasigma s.p.a., taliansko - rifaximín - 15 - antibiotica (proti mikrob. a vÍrusovÝm infekciam)
neofordex
theravia - dexametazón - viacnásobný myelóm - kortikosteroidy na systémové použitie - liečba mnohopočetného myelómu.
fluconazole b. braun 2 mg/ ml infúzny roztok
b.braun melsungen ag, nemecko - flukonazol - 26 - antimycotica (lokÁlne a celkovÉ)
atorvastatin xantis 80 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 40 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 20 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
atorvastatin xantis 10 mg
xantis pharma limited, cyprus - atorvastatín - 31 - hypolipidaemica
orocalm forte 3 mg/ml orálna roztoková aerodisperzia
cassella-med gmbh & co. kg, nemecko - benzydamín - 69 - otorhinolaryngologica
orocalm 1,5 mg/ml orálna roztoková aerodisperzia
cassella-med gmbh & co. kg, nemecko - benzydamín - 69 - otorhinolaryngologica
jakavi
novartis europharm limited - ruxolitinib (ako fosfát) - myeloproliferative disorders; polycythemia vera; graft vs host disease - antineoplastické činidlá - myelofibrosis (mf)jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. polycythaemia vera (pv)jakavi je indikovaný na liečbu dospelých pacientov s polycythaemia vera, ktorí sú odolné voči alebo netolerantné hydroxyurea. graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.